黄芪多糖在Her-2阳性乳腺癌患者化疗中增效减毒的作用及其对血清Her-2-ECD、TAP和疗效的影响  

Effect of Astragalus Polysaccharide on Enhancing Efficacy and Decreasing Toxicity of Chemotherapy in Patients with Her-2 Positive Breast Cancer and Influence on Serum Her-2-ECD,TAP and Efficacy

作　　者：周芹芹 林芬 钟小娟 袁云 ZHOU Qinqin;LIN Fen;ZHONG Xiaojuan;YUAN Yun(Department of Oncology,Xinyu Beihu Hospital,Xinyu 338000,China;不详)

机构地区：[1]新余北湖医院肿瘤科,江西新余338000 [2]新余北湖医院内二科,江西新余338000 [3]新余北湖医院乳腺科,江西新余338000

出　　处：《中国医学创新》2024年第20期57-62,共6页Medical Innovation of China

基　　金：新余市科技计划项目(20233090975)。

摘　　要：目的:探讨黄芪多糖在人表皮生长因子受体-2(human epidermal growth factor receptor-2,Her-2)阳性乳腺癌患者化疗中增效减毒的作用及其对血清人表皮生长因子受体-2胞外段(human epidermal growth factor receptor-2-extracellular domain,Her-2-ECD)、肿瘤异常糖链糖蛋白(tumor abnormal protein,TAP)和疗效的影响。方法:选择2020年1月—2023年6月新余北湖医院收治的90例Her-2阳性乳腺癌患者作为研究对象,将患者随机分为对照组和观察组,各45例。两组均给予TCbHP(多西他赛+卡铂+曲妥珠单抗+帕妥珠单抗)方案治疗;观察组在此基础上给予注射用黄芪多糖治疗。比较两组治疗前后的中医症候积分、血清Her-2-ECD、TAP水平、免疫功能(CD4^(+)、CD8^(+))、白细胞(white blood cell,WBC)水平、乳腺癌患者的生活质量量表(functional assessment of cancer therapy-breast,FACT-B)评分、疗效及不良反应发生率。结果:治疗前,两组各项中医症候积分、Her-2-ECD、TAP、CD4^(+)、CD8^(+)、WBC、FACT-B评分比较,差异均无统计学意义(P>0.05)。治疗后,观察组各项中医症候评分、Her-2-ECD、TAP、CD8^(+)、FACT-B各项评分及不良反应发生率均低于对照组,CD4^(+)、WBC、总有效率均高于对照组,差异均有统计学意义(P<0.05)。结论:黄芪多糖能够改善Her-2阳性乳腺癌化疗患者的化疗效果,减轻化疗带来的毒性反应,提高患者的生活质量。Objective:To investigate the effect of Astragalus Polysaccharide on enhancing efficacy and reducing toxicity during chemotherapy in patients with human epidermal growth factor receptor-2(Her-2)positive breast cancer and influence on serum human epidermal growth factor receptor-2-extracellular domain(Her-2-ECD),tumor abnormal protein(TAP)and therapeutic efficacy.Method:A total of 90 patients with Her-2 positive breast cancer admitted to Xinyu Beihu Hospital from January 2020 to June 2023 were selected as the study objects,and the patients were randomly divided into control group and observation group,with 45 cases in each group.Both groups were treated with TCbHP(Docetaxel+Carboplatin+Trastuzumab+Pertuzumab)regimen.The observation group was given Astragalus Polysaccharide for Injection treatment on this basis.The traditional Chinese medicine syndrome score,serum Her-2-ECD,TAP levels,immune function(CD4^(+),CD8^(+)),white blood cell(WBC)levels,functional assessment of cancer therapy-breast(FACT-B)score before and after treatment,efficacy and incidence of adverse reactions between the two groups were compared.Result:Before treatment,there were no significant differences in traditional Chinese medicine syndrome scores,Her-2-ECD,TAP,CD4^(+),CD8^(+),WBC and FACT-B scores between the two groups(P>0.05).After treatment,the traditional Chinese medicine symptoms scores,Her-2-ECD,TAP,CD8^(+),FACT-B scores and the incidence of adverse reactions in the observation group were lower than those in the control group,and CD4^(+),WBC and total effective rate were higher than those in the control group,the differences were statistically significant(P<0.05).Conclusion:Astragalus Polysaccharide can improve the chemotherapy effect of Her-2 positive breast cancer patients,reduce the toxic reaction caused by chemotherapy,and improve the quality of life of patients.

关 键 词：黄芪多糖 人表皮生长因子受体-2阳性乳腺癌 化疗 人表皮生长因子受体-2胞外段 肿瘤异常糖链糖蛋白 

分 类 号：R737.9[医药卫生—肿瘤]